retatrutide type 2 diabetes phase 2 results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 The MariTide phase 2 trial

GIP fine-tunes insulin response and appears to soften nausea while improving fat handling

For semaglutide, tirzepatide, and most long-acting GLP-1 receptor agonists, labels contain a Boxed Warning about thyroid C-cell tumor findings in rodents and contraindications for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Reported GLP-1 Side Effects and Health Concerns Like all prescription medications, GLP-1 drugs carry potential risks

Freezing can damage the peptide structure, making the medication unsafe or ineffective

Time Constraints: Busy lifestyles lead to reliance on quick, processed options

The Verdict Who Should Consider the Pill